Pharmafile Logo

Orphan Drugs

- PMLiVE

Postcards from China

Part two: The value of innovative medical education in China

- PMLiVE

How should industry support rising stars in the East?

Nick Willhoft of Noveida discusses ways of engaging with Asia's young, influential healthcare thought leaders

- PMLiVE

Demonstrating value and improving access

In today’s dynamic healthcare market, it’s all about how we can demonstrate value and improve access – it is the art of effective communication and education that will enable success

- PMLiVE

Embracing the new paradigm in pharma market access

Pharma needs to change its image from being drug producers to healthcare provider partners

- PMLiVE

The journey to market access 5.0

Few in pharma are unaware of the importance of delivering demonstrable value in collaboration with payers. But are we serious about patient outcomes?

- PMLiVE

Market access webinar series begins with UK healthcare changes

Experts convene for first Sudler & Hennessey and Kantar Health online event

- PMLiVE

Orphan drugs economically viable for pharma

Drugs for rare diseases can generate as much lifetime revenue as medicines for common conditions

- PMLiVE

Astellas Pharma Europe appoint new senior director, market access

Dr Susan Wood was previously senior brand director of the company’s pain management franchise 

- PMLiVE

Interview: Deepak Khanna, ABPI

Collaboration, communication and an appropriate drug pricing scheme are key says ABPI president

- PMLiVE

Major NHS prescription data changes on the way for UK pharma

Webinar will examine the challenges in the UK's forthcoming information revolution

- PMLiVE

Pillars of success in market access

The key to true market access success begins with corporate ownership…

- PMLiVE

Proving value in uncertain times

Industry needs to be perceived as a contributor to healthcare solutions not just a cost

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links